Gastric Cancer - UK Drug Forecasts and Treatment Analysis to 2020

GlobalData, April 2011, Pages: 144

Gastric Cancer - UK Drug Forecasts and Treatment Analysis to 2020

Summary

Global Data, the industry analysis specialist, has released its new report, “Gastric Cancer - UK Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the UK gastric cancer therapeutics market. The report provides comprehensive information on gastric cancer, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the UK gastric cancer therapeutics market. It analyses the treatment usage patterns in the UK gastric cancer therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the UK gastric cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Data’s team of industry experts.

Scope

- An overview of gastric cancer which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized UK gastric cancer therapeutics market revenue, annual cost of therapy and treatment usage patterns data (for hormone therapy and hormone resistant or refractory therapy) from 2001 to 2009, forecast for 11 years to 2020.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals, product positioning and drug sales forecast.
- Analysis of unmet need in the market and target product profile including opportunity for target product.
- Technology trends analytic framework to assess strength of pipeline.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include vascular endothelial growth factor (VGEF) inhibitors, tubulin inhibitors, topoisomerase inhibitors, mammalian target of rapamycin (mTOR) inhibitors and DNA synthesis inhibitors.
- Clinical trials mapping of trials for gastric cancer in UK.
- An overview of the most promising drugs’ including clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.
- Analysis of the current and future market competition in the UK Gastric Cancer therapeutics market. Company profiles including business description, financial overview and SWOT analysis. Key market players covered include Sanofi-aventis, Novartis AG, GlaxoSmithKline, Hoffmann-La Roche Ltd., Eli Lilly and Company, Otsuka and Merck KGaA.
- Analysis of licensing agreements during 2009-2010 in the gastric cancer therapeutics market. M&A analysis which includes M&A deals by size and geography.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
- Direct quotes from key opinion leaders (KOL) or physicians in the gastric cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by
- Understanding the trends shaping and driving the UK gastric cancer therapeutics market.
- Understanding treatment preferences of physicians in disease state and across treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the UK gastric cancer therapeutics market till 2020.
- Quantifying patient population in the UK gastric cancer market to better design product pricing & launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by
- Performing benchmarking analysis and growth opportunities against currently marketed products
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by
- taking a comprehensive look of at the disease pipeline and identifying most promising paradigm shifting products.
- Assessing strength of pipeline bases on first in class, me-too, generic and lifecycle management of products.
- Track drug sales in the UK gastric cancer therapeutics market from 2001 to 2020
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the UK gastric cancer therapeutics market landscape? Identify, understand and capitalize

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Disease Overview
2.1.1 TNM (Tumor, Nodes, Metastasis) Staging System
2.2 Epidemiology
2.3 Etiology
2.4 Symptoms
2.4.1 Initial Symptoms
2.4.2 Symptoms Observed in Later Stages
2.5 Diagnosis
2.5.1 Fecal Occult Blood Test (FOBT)
2.5.2 X-ray of Upper Gastrointestinal Tract (GI Series)
2.5.3 Endoscopy (Gastroscopy)
2.5.4 Computed Tomography (CT)
2.5.5 Biopsy
2.6 Pathology
2.6.1 Grading
2.7 Prognosis
2.8 Treatment
2.8.1 Gastric Cancer Treatment Options
2.9 Treatment Guidelines
2.10 GlobalData Report Guidance
3 Market Characterization
3.1 The UK
3.1.1 Market Size
3.1.2 Drivers and Restraints
3.1.3 Impact on the Market
3.1.4 Forecasts
3.1.5 Drug Sales
3.1.6 Pricing and Reimbursements
3.2 Key Takeaway
4 Gastric Cancer Market: Competitive Assessment
4.1 Strategic Competitor Assessment
4.1.1 Overview
4.1.2 Benchmarking
4.1.3 Current Competitor Assessment
4.2 Launch Analysis and Sales Forecasts
4.3 Product Profiles of Major Marketed Drugs in the Gastric Cancer Market
4.3.1 Herceptin (trastuzumab)
4.3.2 Taxotere (docetaxel)
4.3.3 Xeloda
4.4 Key Takeaway
5 Gastric Cancer Market: Pipeline Assessment
5.1 Overview
5.2 Pipeline Analysis by Phase of Development
5.3 Pipeline by Mechanism of Action
5.4 Strategic Pipeline Assessment
5.4.1 Technology Trends Analytic Framework
5.5 Gastric Cancer – Promising Drugs Under Clinical Development
5.6 Partners in Development
5.6.1 Licensing Agreements
5.6.2 Research and Development Partnership Agreements
5.6.3 Technology and Diagnostic Agreements
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 Tykerb (Lapatinib)
5.7.2 Afinitor (Everolimus)
5.7.3 IMC-1121B (ramucirumab)
5.7.4 Cetuximab plus capecitabine and cisplatin
5.7.5 Apatinib (YN968DI)
5.8 Key Takeaway
6 Clinical Trials Mapping
6.1 Clinical Trials
6.1.1 Clinical Trials by Status
6.1.2 Clinical Trials by Country
6.1.3 Clinical Trials by Phase
6.1.4 Clinical Trials by Sponsor Type
6.1.5 Clinical Trials – Leading Sponsors
6.1.6 Clinical Trials – Leading Company Sponsors by Phase
6.2 Patient Recruitment
7 Opportunity and Unmet Need
7.1 Unmet Need
7.2 Opportunity for Target Products
7.3 Key Takeaway
8 Strategic Assessment
8.1 Key Events Impacting the Future Market
8.2 Market Impact Analysis
8.3 Future Market Scenario
9 Gastric Cancer Market: Future Players
9.1 Introduction
9.2 Novartis AG
9.2.1 Business Description
9.2.2 Financial Overview
9.2.3 Gastric Cancer Pipeline
9.2.4 SWOT Analysis
9.3 GlaxoSmithKline
9.3.1 Business Description
9.3.2 Financial Overview
9.3.3 Gastric Cancer Pipeline
9.3.4 SWOT Analysis
9.4 Hoffmann-La Roche Ltd.
9.4.1 Business Description
9.4.2 Financial Performance
9.4.3 Gastric Cancer Pipeline
9.4.4 SWOT Analysis
9.5 Eli Lilly and Company
9.5.1 Business Description
9.5.2 Financial Overview
9.5.3 Gastric Cancer Pipeline
9.5.4 SWOT Analysis
9.6 Otsuka Holdings Co., Ltd./Otsuka Pharmaceutical Co., Ltd.
9.6.1 Business Description
9.6.2 Gastric Cancer Products
9.7 Merck KGaA
9.7.1 Business Description
9.7.2 Financial Overview
9.7.3 Gastric Cancer Pipeline
9.7.4 SWOT Analysis
10 Gastric Cancer Market: Players in the Gastric Cancer Market
10.1 Sanofi-aventis
10.1.1 Business Description
10.1.2 Financial Overview
10.1.3 SWOT Analysis
10.1.4 Oncology Focus
11 M&A Analysis
11.1 Key Highlights
11.2 Key Deals’ Analysis
11.2.1 CrystalGenomics Completes Merger with BexPharm
11.2.2 Astellas Pharma Acquires OSI Pharmaceuticals
11.2.3 Eli Lilly Acquires ImClone
11.2.4 Roche Acquires Additional 9.8% Stake in Chugai Pharmaceuticals
12 Appendix
12.1 Market Definitions
12.2 Abbreviations
12.3 Research Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Forecasting
12.3.4 Primary Research
12.3.5 Expert Panel validation
12.3.6 Contact Us
12.3.7 Disclaimer
12.3.8 Sources

1.1 List of Tables
Table 1: Gastric Cancer Therapeutics Market, Global, Staging of Gastric Cancer, 2010
Table 2: Gastric Cancer Therapeutics Market, Global, Risk Factors, 2010
Table 3: Gastric Cancer, Global, Results of GI Series X-ray, 2010
Table 4: Gastric Cancer, Global, WHO Classification of Gastric Carcinomas, 2010
Table 5: Gastric Cancer, Global, Five Year Relative Survival by Stage, 2010
Table 6: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011
Table 7: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2002-2010
Table 8: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2010
Table 9: Gastric Cancer Therapeutics Market, the UK, Patient Volume (Absolute), 2002-2010
Table 10: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns (’000s), 2002-2010
Table 11: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2010-2020
Table 12: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2010-2020
Table 13: Gastric Cancer Therapeutics Market, the UK, Patient Volume (Absolute), 2010-2020
Table 14: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns (’000s), 2010-2020
Table 15: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2002-2010
Table 16: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2011-2020
Table 17: Gastric Cancer, Global, Clinical Endpoints for Benchmarking, 2010
Table 18: Gastric Cancer, Global, Chemotherapy, Safety Profile of Approved Treatment, 2010
Table 19: Gastric Cancer, Global, Benchmarking of Major Marketed Products, 2010
Table 20: Gastric Cancer Therapeutics – Phase III Pipeline, 2010
Table 21: Gastric Cancer Therapeutics – Phase II Pipeline, 2010
Table 22: Gastric Cancer Therapeutics – Phase I Pipeline, 2010
Table 23: Gastric Cancer Therapeutics – Preclinical Pipeline, 2010
Table 24: Mechanism of Action for the ‘Other’ molecules in the Figure Above
Table 25: Gastric Cancer – Most Promising Drugs Under Clinical Development, 2010
Table 26: Gastric Cancer, Global, Licensing Agreements, 2007-2010
Table 27:Gastric Cancer, Global, Research and Development Partnership Agreements, 2009-2010
Table 28: Gastric Cancer, Global, Technology and Diagnostic Agreements, 2009-2010
Table 29: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011
Table 30: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011
Table 31: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011
Table 32: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011
Table 33:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011
Table 34:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011
Table 35:Gastric Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011
Table 36: Novartis AG – Clinical Pipeline for Gastric Cancer, 2010
Table 37: GlaxoSmithKline – Clinical Pipeline for Gastric Cancer, 2011
Table 38: Roche – Clinical Pipeline for Gastric Cancer, 2011
Table 39: Eli Lilly and Company – Clinical Pipeline for Gastric Cancer, 2011
Table 40: Otsuka Holdings Co., Ltd. – Clinical Pipeline for Gastric Cancer, 2011
Table 41: Otsuka Holdings Co., Ltd. – Clinical Pipeline for Gastric Cancer, 2011
Table 42: Gastric Cancer, Global, M&A Deals, 2010

1.2 List of Figures
Figure 1: Gastric Cancer, Global, Illustration of Subtotal and Total Gastrectomy, 2011
Figure 2: Gastric Cancer Therapeutics Market, Global, Treatment Guidelines, 2010
Figure 3: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2002-2010
Figure 4: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2002-2010
Figure 5: Gastric Cancer Therapeutics Market, the UK, Patient Volume (’000s), 2002-2010
Figure 6: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns (’000s), 2002-2010
Figure 7: Gastric Cancer Therapeutics Market, the the UK, Market Drivers and Restraints, 2009
Figure 8: Gastric Cancer Therapeutics Market, the UK, Historical Events Impact on the Market, 2010
Figure 9: Gastric Cancer Therapeutics Market, the UK, Sales Value ($m), 2010-2020
Figure 10: Gastric Cancer Therapeutics Market, the UK, Annual Cost of Therapy ($), 2010-2020
Figure 11: Gastric Cancer Therapeutics Market, the UK, Patient Volume (’000s), 2010-2020
Figure 12: Gastric Cancer Therapeutics Market, the UK, Treatment Usage Patterns (’000s), 2010-2020
Figure 13: Gastric Cancer Therapeutics Market, the UK, Future Market Drivers and Restraints, 2010-2020
Figure 14: Gastric Cancer Therapeutics Market, the UK, Gastric Cancer Drug Sales ($m), 2002-2020
Figure 15: Gastric Cancer, Global, Strategic Competitor Assessment of Major Marketed Drugs, 2011
Figure 16: Gastric Cancer Therapeutics Market, UK, Sales Forecast by Therapies, 2001-2020
Figure 17: Gastric Cancer, UK, Herceptin, Sales ($m), 2010-2020
Figure 18: Gastric Cancer, UK, Taxotere,, Sales ($m), 2006-2020
Figure 19: Gastric Cancer, UK, Xeloda, Sales ($m), 2010-2020
Figure 20: Gastric Cancer, Global, Clinical Trials by Phase of Development, 2010
Figure 21: Gastric Cancer, Global, Pipeline by Mechanism of Action, 2010
Figure 22: Gastric Cancer, Global, Technology Trends Analytic Framework of Pipeline Drugs, 2011
Figure 23: Gastric Cancer, Global, Technology Trends Description of Pipeline Drugs, 2011
Figure 24: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Status, January 2011
Figure 25: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Country, January 2011
Figure 26: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Phase, January 2011
Figure 27: Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, January 2011
Figure 28: Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January 2011
Figure 29: Gastric Cancer Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January 2011
Figure 30: Gastric Cancer Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January 2011
Figure 31: Gastric Cancer, UK, Median Overall Survival for Gastric Cancer Patients, 2011
Figure 32: Gastric Cancer, UK, Opportunity and Unmet Need, 2010
Figure 33: Gastric Cancer, Global, Key Events Impacting the Future Market
Figure 34: Gastric Cancer, UK, Implications for Future Market Competition, 2011
Figure 35: Gastric Cancer Therapeutic Market – Clinical Pipeline by Company, 2010
Figure 36: Gastric Cancer, Global, Novartis, SWOT Analysis 2010
Figure 37: Gastric Cancer, Global, GlaxoSmithKline, SWOT Analysis 2010
Figure 38: Gastric Cancer, Global, Roche, SWOT Analysis 2010
Figure 39: Gastric Cancer, Global, Eli Lilly and Company, SWOT Analysis 2010
Figure 40: Gastric Cancer, Global, Merck KGaA, SWOT Analysis 2010
Figure 41: Gastric Cancer, Sanofi-aventis, Major Pharmaceutical Drugs 2010
Figure 42: Gastric Cancer, Sanofi-aventis Pasteur, Diseases Under Each Vaccination Area 2010
Figure 43: Gastric Cancer, Global, Sanofi-aventis, SWOT Analysis, 2010
Figure 44: Gastric Cancer, Sanofi-aventis, Therapeutic Segment Share of Pipeline, 2010
Figure 45: GlobalData Market Forecasting Model

Novartis AG
GlaxoSmithKline
Hoffmann-La Roche Ltd.
Eli Lilly and Company
Otsuka Holdings Co., Ltd./Otsuka Pharmaceutical Co., Ltd.
Merck KGaA
Sanofi-aventis

Customers who bought this item also bought

• UK/Ireland Biotechnology Sector: Clinical Phase Drug Development Pipeline
• Healthcare, Regulatory and Reimbursement Landscape - UK
• UK Pharmaceutical Market Overview - Pricing and reimbursement challenges dampen future growth
• Global Gastric Cancer Epidemiology and Patient Flow Analysis - 2012
• Why Do UK Patients Not Seek Help from the Doctor, When They Should?
• Industrial Pharmaceutical Microbiology: Standards & Controls
• The UK Vitamin and Dietary Supplements Demand and Forecast
• Europe Vitamin and Dietary Supplements Demand and Forecast
• Clinical Research Manual
• Global Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2012